Thursday, July 30, 2026

Good Afternoon!

Medical breakthroughs often begin long before they make headlines. Today's partner, Cytonics, is offering Flyover readers a look at its osteoarthritis therapy, which has completed a Phase 1 safety trial and is now moving into the next stage of development.

— Cole, CEO

Over 7,500 investors have already joined Cytonics, a biotech startup developing what could be the first cure for osteoarthritis (OA). And they aim to win one of medicine’s biggest unsolved opportunities.

Over $560 billion is spent managing OA every year. For 500+ million patients worldwide*, the options have always been the same: manage the pain, slow the damage, repeat.

Cytonics may be about to change that.

Here's why this emerging biotech is turning heads, and why early-stage investors are paying attention:

Proven technology. Their first-generation therapy has already treated 10,000+ patients.
A scalable path forward. Cytonics is now developing a mass-producible version aimed at FDA approval.
A true disease-modifier. If approved, Cytonics' therapy would be the first to halt cartilage destruction and promote regrowth, rather than just dull the pain.

And this mass-producible, 200% more potent version of their first-gen therapy has just cleared Phase 1 safety trials. Now, the company is moving into the next phase of development.

If successful, this is historically when Big Pharma acquires biotech targets: when efficacy data exists but no price has been set.

Merck acquired Prometheus for $10.8 billion. GSK acquired Bellus for $2 billion**. While nothing's guaranteed, an uncured $560 billion disease is exactly what Big Pharma looks for.

Potential medical breakthroughs like this are rare. The chance to invest in an early clinical stage is even rarer.

Time’s almost up to become an early-stage shareholder. Join 7,500+ people and invest in Cytonics before the round closes.

*Source: The Lancet Rheumatology **Sources: Merck / GSK *Comparisons to acquisitions are for informational purposes only This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://invest.cytonics.com/ Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal. *Phase 1 clinical trials are designed primarily to assess safety and tolerability and do not establish efficacy. Clinical trial results are preliminary, and there can be no assurance that future trials will be successful or that any product candidate will receive regulatory approval.

Unsubscribe from promotional offers, but continue to receive The Flyover

Unsubscribe from all The Flyover emails

The Flyover, LLC
1910 Thomes Ave.
Cheyenne WY 82001